How We Are Experimenting With Talent

Drug development entails risk. Clinical trials are elaborate and expensive experiments, and unfortunately sometimes promising hypotheses prove false. This can be frustrating and even painful at times, but ultimately such are risks worth taking, since new and improved medicines can mean the difference between life and death for patients with serious diseases. At Roivant, we embrace taking calculated risks that have the potential to meaningfully benefit patients. We tend to focus on disease areas where the magnitude of investment from industry is disproportionately low relative to societal medical needs. This approach pushes us to develop therapies in a great diversity of illnesses including Parkinson’s disease, diabetes, prostate cancer, sickle cell anemia, ultra-rare fatal pediatric conditions, and several others where the current standard of care is insufficient.